Department of Entomology, University of California, Davis 95616, USA.
J Infect Dis. 2013 Sep;208(6):1026-33. doi: 10.1093/infdis/jit273. Epub 2013 Jun 17.
Antibodies induced by infection with any 1 of 4 dengue virus (DENV) serotypes (DENV-1-4) may influence the clinical outcome of subsequent heterologous infections. To quantify potential cross-protective effects, we estimated disease risk as a function of DENV infection, using data from longitudinal studies performed from September 2006 through February 2011 in Iquitos, Peru, during periods of DENV-3 and DENV-4 transmission.
DENV infections before and during the study period were determined by analysis of serial serum samples with virus neutralization tests. Third and fourth infections were classified as postsecondary infections. Dengue fever cases were detected by door-to-door surveillance for acute febrile illness.
Among susceptible participants, 39% (420/1077) and 53% (1595/2997) seroconverted to DENV-3 and DENV-4, respectively. Disease was detected in 7% of DENV-3 infections and 10% of DENV-4 infections. Disease during postsecondary infections was reduced by 93% for DENV-3 and 64% for DENV-4, compared with primary and secondary infections. Despite lower disease rates, postsecondary infections constituted a significant proportion of apparent infections (14% [for DENV-3 infections], 45% [for DENV-4 infections]).
Preexisting heterotypic antibodies markedly reduced but did not eliminate the risk of disease in this study population. These results improve understanding of how preinfection history can be associated with dengue outcomes and DENV transmission dynamics.
感染任何一种 4 种登革热病毒(DENV)血清型(DENV-1-4)均可诱导抗体产生,这些抗体可能会影响后续异型感染的临床结果。为了量化潜在的交叉保护作用,我们利用 2006 年 9 月至 2011 年 2 月期间在秘鲁伊基托斯进行的纵向研究的数据,来估计 DENV 感染与疾病风险之间的关系,该研究期间存在 DENV-3 和 DENV-4 传播。
通过病毒中和试验分析连续血清样本,确定研究期间之前和期间的 DENV 感染情况。将第三次和第四次感染归类为二次感染。通过上门监测急性发热性疾病来发现登革热病例。
在易感参与者中,分别有 39%(420/1077)和 53%(1595/2997)的血清学转化为 DENV-3 和 DENV-4。DENV-3 感染中有 7%和 DENV-4 感染中有 10%出现了疾病。与原发性和继发性感染相比,DENV-3 和 DENV-4 的二次感染的疾病发生率分别降低了 93%和 64%。尽管疾病发生率较低,但二次感染在显性感染中仍占很大比例(DENV-3 感染为 14%,DENV-4 感染为 45%)。
在本研究人群中,预先存在的异型抗体显著降低了疾病风险,但并未完全消除这种风险。这些结果增进了对感染前史如何与登革热结局和 DENV 传播动力学相关联的理解。